2L6S

Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide

• PDB DOI: https://doi.org/10.2210/pdb2L6S/pdb

• Classification: ANTIVIRAL PROTEIN
• Mutation(s): No 


• Deposited: 2010-11-24 Released: 2011-01-19 
• Deposition Author(s): Forssmann, W., The, Y., Stoll, M., Adermann, K., Albrecht, U., Barlos, K., Busmann, A., Canales-Mayordomo, A., Gimenez-Gallego, G., Hirsch, J., Jimenez-Barbero, J., Meyer-Olson, D., Muench, J., Perez-Castells, J., Standker, L., Kirchhoff, F., Schmidt, R.E.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 20 
• Conformers Submitted: 14 
• Selection Criteria: structures with the lowest energy 

Literature

Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.

Forssmann, W.G., The, Y.H., Stoll, M., Adermann, K., Albrecht, U., Barlos, K., Busmann, A., Canales-Mayordomo, A., Gimenez-Gallego, G., Hirsch, J., Jimenez-Barbero, J., Meyer-Olson, D., Munch, J., Perez-Castells, J., Standker, L., Kirchhoff, F., Schmidt, R.E.

(2010) Sci Transl Med 2: 63re3-63re3

• PubMed: 21178138 
• DOI: https://doi.org/10.1126/scitranslmed.3001697
• Primary Citation of Related Structures:  
  2L6S, 2L6T


• PubMed Abstract: 
  

  To infect host cells, most enveloped viruses must insert a hydrophobic fusion peptide into the host cell membrane. Thus, fusion peptides may be valuable targets for developing drugs that block virus entry. We have shown previously that a natural 20-residue fragment of α(1)-antitrypsin, designated VIRus-Inhibitory Peptide (VIRIP), that binds to the gp41 fusion peptide of HIV-1 prevents the virus from entering target cells in vitro. Here, we examine the efficacy of 10-day monotherapy with the optimized VIR-576 derivative of VIRIP in treatment-naïve, HIV-1-infected individuals with viral RNA loads of ≥10,000 copies per ml. We report that at the highest dose (5.0 grams per day), intravenous infusion of VIR-576 reduced the mean plasma viral load by 1.23 log(10) copies per ml without causing severe adverse effects. Our results are proof of concept that fusion peptide inhibitors suppress viral replication in human patients, and offer prospects for the development of a new class of drugs that prevent virus particles from anchoring to and infecting host cells.

---

Organizational Affiliation: 

Department of Immunology and Rheumatology, Hannover Medical University, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 2.25 kDa 
• Atom Count: 160 
• Modelled Residue Count: 20 
• Deposited Residue Count: 20 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
VIR-576	A	20	N/A	Mutation(s): 0

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 20 
• Conformers Submitted: 14 
• Selection Criteria: structures with the lowest energy 

Structure Validation

Entry History 

Deposition Data

• Released Date: 2011-01-19 
Deposition Author(s): Forssmann, W., The, Y., Stoll, M., Adermann, K., Albrecht, U., Barlos, K., Busmann, A., Canales-Mayordomo, A., Gimenez-Gallego, G., Hirsch, J., Jimenez-Barbero, J., Meyer-Olson, D., Muench, J., Perez-Castells, J., Standker, L., Kirchhoff, F., Schmidt, R.E.

Revision History  

• Version 1.0: 2011-01-19
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance
• Version 1.2: 2024-05-01
  Changes: Data collection, Database references